Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGEN1571 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation: AGEN1571 | EXPERIMENTAL | Participants will receive AGEN1571 monotherapy. |
| Dose Escalation: AGEN1571 + Balstilimab | EXPERIMENTAL | Participants will receive AGEN1571 with balstilimab. |
| Dose Escalation: AGEN1571 + Botensilimab | EXPERIMENTAL | Participants will receive AGEN1571 with botensilimab. |
| Dose Escalation: AGEN1571 + Balstilimab + Botensilimab | EXPERIMENTAL | Participants will receive AGEN1571 with balstilimab and botensilimab. |
| Dose Expansion | EXPERIMENTAL | AGEN1571 administered at the RP2D for monotherapy or any combination therapy. |
| Name | Type | Description |
|---|---|---|
| AGEN1571 | DRUG | A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously. |
| Balstilimab | DRUG | A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously. |
| Botensilimab | DRUG | A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously. |
Inclusion Criteria: 1. Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures (participation in genetic testing is optional). 2. Histologically confirmed diagnosis of a solid tumor that is currently metastatic or locally advance...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AGEN1571 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with advanced solid tumor malignancies.
AGEN1571 is being developed by Agenus Inc., a biopharmaceutical company. Agenus Inc. is publicly traded on the NASDAQ under the ticker symbol AGEN. The company is conducting clinical research to evaluate the safety and efficacy of AGEN1571 in patients with advanced solid tumors.
AGEN1571 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 1 study of AGEN1571 has been completed, and the drug remains in early-stage clinical development for advanced solid tumors.
AGEN1571 has been studied in one clinical trial, identified as NCT05377528, titled "Study of AGEN1571 in Participants With Advanced Solid Tumors." This Phase 1 trial was conducted in the United States and enrolled 22 participants aged 18 years and older. The trial has been completed.
No alternative names for AGEN1571 have been identified. The drug is known by its code name AGEN1571 and is being developed by Agenus Inc. It is a distinct investigational small molecule being studied for the treatment of advanced solid tumors.